Laurus Labs Q4 Results: Cons PAT Increased 19% to Rs 279 Crore, Revenue Rises 5%

Why It Matters

The earnings beat underscores Laurus Labs' expanding CDMO and generics businesses, boosting investor confidence and signaling stronger cash flow for future growth and shareholder returns.

Key Takeaways

• Q4 PAT rose 19% to Rs 279 cr ($33.6 M)
• Revenue grew 5% to Rs 1,812 cr ($21.8 M)
• EBITDA up 10% YoY, reaching Rs 523 cr ($6.3 M)
• Gross margin expanded to 61.4%, 690 bps YoY improvement
• Full‑year profit surged 148% to Rs 889 cr ($107 M)

Pulse Analysis

Laurus Labs delivered a robust fourth‑quarter performance, with net profit climbing 19% year‑over‑year to Rs 279 crore (about $33.6 million). The top line rose 5% to Rs 1,812 crore ($21.8 million), driven by higher demand in both its contract development and manufacturing organization (CDMO) segment and its affordable medicines portfolio. EBITDA expanded 10% YoY to Rs 523 crore ($6.3 million), reflecting improved operating leverage and a notable 690‑basis‑point jump in gross margins to 61.4%, the highest in the company's recent history.

Margin expansion was complemented by disciplined spending, with R&D outlays at Rs 76 crore ($0.9 million), representing 4.2% of revenue. The board’s approval of a second interim dividend of Rs 1.20 per share signals confidence in cash generation and a commitment to returning capital to shareholders. Operating cash flow surged, aided by better net working capital management, while net‑debt‑to‑EBITDA ratios continued to improve, positioning the firm for sustained capital investment without compromising financial stability.

Strategically, Laurus Labs’ full‑year results highlight a 148% profit surge to Rs 889 crore ($107 million) and a 23% revenue jump to Rs 6,813 crore ($82 million), underscoring the success of its dual‑track growth model. The CDMO business is benefiting from global pharma outsourcing trends, while the generics division capitalizes on price‑sensitive markets. With strong cash flow, expanding margins, and a clear dividend policy, Laurus Labs is well‑placed to capture further market share and deliver long‑term value to investors.